US 7,785,647 B2Grant

Methods of providing antioxidants to a drug containing product

Issue Date:2010-08-31

•16 Claims

•3 Drawing Sheets

Abstract

A method of providing an antioxidant to a medical device is described.

Metadata

Assignee

Advanced Cardiovascular Systems, Inc.

Inventor

Ni Ding

Application Information

Application Number:US 11/189,216

Filing Date:2005-07-25

Priority Date:2005-07-25

Art Unit:1711

Classifications

IPC:

A61L33/00

Patent Drawings (3 sheets)

Description

BACKGROUND OF THE INVENTION

[0001] 1. Field of the Invention

[0002] This invention generally relates to a method of providing a volatile antioxidant (e.g., butylated hydroxytoluene (BHT) and/or butylated hydroxyanisole (BHA)) to a package with a medical device such as a drug-delivery stent.

[0003] 2. Description of the Background

[0004] Drug delivery stent is becoming a common practice to treat, prevent or ameliorate a cardiovascular condition or a related medical condition. In manufacture of drug coated stent, the drug or drug-polymer formulation is first applied onto the stent as a coating. The stent then undergoes many post coating treatments, which may involve heat, moisture, pressure, sterilized gas, electron beam or radiation. After the stents are packaged, it will face shelf life challenges. For example, if a drug is oxygen sensitive, oxidation degradation may occur during these steps. One of the commonly used methods to circumvent these shortcomings is to include one or more antioxidants in the stent coating formulation. Butylated hydroxytoluene (BHT) and butylated hydroxyanisole (BHA) are commonly used antioxidant in food industry. For instance, many drugs such as limus family (e.g. everolimus, sirolimus, ABT 578, biorolimus) and paclitaxel are oxygen sensitive. To preserve the drug integrity, antioxidant was introduced into the drug coating formulation. Among them are BHT and BHA.

[0005] BHA is a volatile solid with melting temperature of 45 to 63° C. BHT can be sublimated at temperatures under its melting point (70° C.). Studies have shown that in some stent coating processes, up to 40% BHT may be lost during standard ethylene oxide (ETO) sterilization process, which involves heat and moisture.

[0006] Therefore, there is a need for the preservation of BHT and/or BHA in a stent manufacturing process. There is another need for the incorporation of BHT and/or BHA into the drug product.

[0007] The embodiments described below address the above described problems and needs.

SUMMARY OF THE INVENTION

[0008] Provided herein is a method for providing a volatile antioxidant (e.g., BHT and/or BHA) to a medical device (e.g., drug delivery stent) during and/or after the manufacturing process of the device. The method includes adding an antioxidant (e.g., BHT and/or BHA) to a medical device or a coating for the device, causing the antioxidant to permeate into a medical device or a coating for the device, or otherwise providing an antioxidant in the proximity or surrounding of a medical device (e.g., a stent). In some embodiments, the antioxidant permeates into a medical device or a coating of the medical device so as to provide the antioxidant in the device and/or coating or to enhance the content of the antioxidant in the device and/or coating. The antioxidant can be the same or different from the antioxidant in the device or coating should the device or coating already include one.

[0009] The medical device can be a stent that can be a metallic or polymeric stent which is biodegradable or nondegradable. The stent itself or a coating on the stent may include a bioactive agent such as paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), pimecrolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, bioactive RGD, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.

BRIEF DESCRIPTION OF DRAWINGS

[0010] FIG. 1 shows one embodiment of the present invention where an antioxidant is placed in a porous or permeable container in a product package containing a medical device;

[0011] FIG. 2 shows another embodiment of the present invention where an antioxidant is present between the product packaging that includes a medical device and a secondary packaging in that the antioxidant is placed in the outer layer of the product packaging;

[0012] FIG. 3 shows another embodiment of the present invention where an antioxidant is present between the product packaging that includes a medical device and a secondary packaging in that the antioxidant is placed in the inner layer of the secondary packaging;

[0013] FIG. 4 shows butylated hydroxytoluene (BHT) powder sublimation at different temperature;

[0014] FIG. 5 shows BHT retained in a coating at different temperatures.

DETAILED DESCRIPTION

[0015] Provided herein is a method for providing an antioxidant (e.g., a volatile antioxidant), in some embodiments, butylated hydroxytoluene (BHT) and/or butylated hydroxyanisole (BHA), to a medical device such as a drug delivery stent or to a coating on the device during the manufacturing process or storage of the device. In some embodiments, the method includes causing an antioxidant (e.g., BHT and/or BHA) to permeate into a medical device or a coating on the device or otherwise providing an antioxidant in the proximity of a medical device (e.g., a stent) to allow the antioxidant to permeate into the medical device or the coating of the medical device so as to provide the antioxidant to the device or the coating or to enhance the content of the antioxidant in the device or the coating. The device or coating can include a drug. The antioxidant can be the same or different from the antioxidant in the device or coating should the device or the coating already include one. In some embodiments, the device or coating does not include an antioxidant such that the method provides for one to be added in the device or coating. In some other embodiments, the antioxidant added to a medical device or coating by the method described herein may compensate the whole or part of the loss of the antioxidant in the medical device (e.g., stent) or coating during the manufacture or storage of the medical device. In one embodiment, the antioxidant is added to the device or coating in an amount more than the loss of the antioxidant in the medical device or coating from the manufacturing process or during storage.

[0016] The medical device can be a stent that can be a metallic or polymer stent. The stent can be a biodegradable stent or a nondegradable stent. The stent may have a polymeric coating that may include a bioactive agent such as everolimus. The coating can be biodegradable or nondegradable. In some embodiments, the stent, itself, can be a polymeric biodegradable, bioerodable or bioabsorbable stent, terms which are used interchangeably unless specifically indicated, which can include the bioactive agent embedded in the body of the stent or coating in the stent. The stent can be intended for neurovasculature, carotid, coronary, pulmonary, aorta, renal, biliary, iliac, femoral, popliteal, or other peripheral vasculature. The stent can be used to treat, prevent, or ameliorate a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.

Permeation of a Volatile Antioxidant into a Coating

[0017] In one embodiment, an amount (e.g., ranging from about 1 mg to about 10 g) of a volatile antioxidant can be placed in a porous or permeable container and then place the container inside a product package such as a Tyvek pouch within which a medical device (e.g., stent) is packaged. This embodiment is shown in FIG. 1, where the Tyvek package 100 contains a stent 110 and a porous or permeable container 120, which contains antioxidant 130. Thus, in one commercial embodiment, a kit is provided having a sterile device, such as a drug delivery stent, and an antioxidant included in the kit packaging. The stent can be packaged alone or may be pre-crimped on a delivery catheter or a balloon catheter, ready for use by a health care provider. The figures do not illustrate a catheter assembly for delivery of the stent but such devices are well known to one having ordinary skill in the art. For example, permeation of BHT into a polymeric coating can be achieved by placing a certain amount (e.g., 500 mg) of BHT in a porous or permeable container and placing the container inside a Tyvek pouch within which a medical device such as a stent is packaged prior to ethylene oxide (ETO) sterilization. During the ETO process (typically at 55° C.), BHT sublimates to form a BHT gas. The BHT gas then fills in the Tyvek pouch. The permeation rate of molecules through a Tyvek pouch is size sensitive. Larger molecules have a smaller permeation rate while smaller molecules have a larger permeation rate. Permeation rate of ETO, cresol and toluene on one kind of Tyvek material are listed below as examples of molecular size dependence on the permeation rate (Table 1).

[0018]

	TABLE 1

	Material	Time to reach permeation rate of 1 μg/cm²/min)


	ETO	120
	Cresol	206
	Toluene	>480

Since BHT is much more bulky than ethylene oxide, it is expected that the permeation rate for BHT is significantly lower than ethylene oxide gas. Depending on the type of Tyvek pouch, the permeation rate for ETO gas and moisture could be significantly different from the bulky BHT molecule. Accordingly, over time, the Tyvek pouch can be over-saturated with BHT, which could reduce the escape of BHT from coated stents and even may lead to reverse diffusion of BHT into a coating such as the coating of a drug-delivery stent, increasing BHT content in the coating of the stent. Should the coating not include an antioxidant, such process may lead to the incorporation of the antioxidant into the coating. In some embodiments, prior to the use of the device, the level of antioxidant can be lower than the initial level of the antioxidant. In some embodiments, as mentioned previously, the level is higher. It is also possible that the level of antioxidant is preserved, e.g., about ±5%, about ±10%, about ±15%, about ±20%, or about ±30%.

[0019] In another embodiment, an amount (e.g., an amount from about 1 mg to about 20 g) of an antioxidant or a volatile antioxidant (e.g., BHT and/or BHA) can be placed intimately close to a medical device, such as bioerodable polymeric stent or polymeric coated metallic stent, which is packaged within a package (e.g., Tyvek package), in a gas impermeable secondary package after sterilization. In some embodiments, it can be before sterilization. As shown in FIG. 2, the secondary packaging 200 encloses a Tyvek packaging 210, which includes a stent 220. The kit can include the stent 220 by itself or pre-crimped on a delivery catheter or balloon catheter. On the outer layer of the Tyvek packaging 210, an antioxidant 230 is placed. The gas impermeable secondary package can be made of any plastic or non-plastic material. In this embodiment, the volatile antioxidant (e.g., BHT and/or BHA) evaporates over time, fills the space and prevents the infiltrated oxygen from damaging the product. To speed up the sublimation, one may optionally heat the entire finished package to a temperature e.g., e.g., between 20° C. and, 70° C. (e.g., about 30° C., about 40° C., about 50° C., or about 60° C.) for a short period of time (e.g., about 10 seconds, about 20 seconds, about 30 seconds, about 40 seconds, about 50 seconds, about 60 seconds, about 90 seconds, or about 120 seconds) to allow enough antioxidant gas (e.g., BHT gas) to fill the space of the secondary package. The heating can be achieved by any heating means known in the art. It is noteworthy that, in this embodiment, the volatile antioxidant (e.g., BHT) is not added directly to the polymer and/or drug formulation.

[0020] In another embodiment, the shelf life of a medical device e.g., stent) can be improved by providing a gas impermeable secondary package, placing (e.g., by coating) an amount (e.g., about 1 mg to about 20 g) of an antioxidant (e.g., BHT particles or BHT film) in the inner-layer or inside of the secondary package, and placing a sterilized product package (e.g., Tyvek package) containing a drug-delivery stent that can include a antioxidant (e.g., BHA and/or BHT) into the secondary package. The sterilization can be by commonly known techniques including ETO. In some embodiments, sterilization can be subsequent to placement in the secondary package. As shown in FIG. 3, the secondary packaging 200 encloses a Tyvek packaging 210, which includes a stent 220. On the inner layer or inside of the secondary packaging 200, an antioxidant 230 is placed. The antioxidant will then evaporate to form a vapor which protects the enclosed product. The antioxidant can be the same or different from the antioxidant in the medical device. As with any other embodiments of the invention, such embodiment can be in the form of a labeled medical kit with a stent or the stent premounted on a delivery or balloon catheter.

[0021] In a further embodiment, the product shelf life can be prolonged by placing (e.g., by coating) an amount (e.g., about 1 mg to about 20 g) of a volatile antioxidant (e.g., BHT particles or BHT film) on the outer layer of a product package (e.g., Tyvek package) containing a medical device (e.g., stent) that can include a antioxidant and placing the product package inside a gas impermeable secondary package. The medical device can be sterilized prior to placement in the secondary package or alternatively after its placement. The antioxidant then evaporates over the time to protect the drug from oxidation. It should be noted that the antioxidant can be added between the two packaging in solid, fluid or gas form and is not limited to a coating form. The antioxidant can be the same or different from the antioxidant in the medical device should the device already include one. Unless otherwise specifically indicated, the term “gas impermeable” means impermeable to an antioxidant gas, preferably to BHT or BHA (conversely, the term “permeable” means permeable to an antioxidant gas). Again, such an assembly can be in the form of a medical kit with a stent or the stent premounted on a catheter.

[0022] In a further embodiment, an antioxidant can be added to the formulation from which the device is made or from which the device is coated. For example, the antioxidant can be added to the polymer/solvent coating formulation with or without a drug. The formulation could be used to form the reservoir layer or a topcoat layer on top of the reservoir layer. The topcoat layer can be free of drug although in certain circumstances some drug migration might occur.

[0023] The method described herein is applicable to any medical device coated with one or more drugs or bioactive agents with or without a polymeric material and optionally with one or more biobeneficial materials. The drug can be blended, conjugated, bonded or combined with a polymer. The method described herein is also applicable to any biodurable or bioabsorable (which can include bioerodable or biodegradable) device formed of a polymeric material optionally with one or more bioactive agents. The drugs or agents can be compounded in the body of the device or coated on the device. The biocompatible polymer useful for forming a coating composition can be any biocompatible polymer known in the art, which can be biodegradable or nondegradable. Biodegradable is intended to include bioabsorbable or bioerodable, unless otherwise specifically stated. Representative examples of polymers that can be used to coat a medical device in accordance with the present invention include, but are not limited to, poly(ester amide), ethylene vinyl alcohol copolymer (commonly known by the generic name EVOH or by the trade name EVAL), poly(L-lactide), poly(D-lactide), poly(D,L-lactide), poly(D,L-lactide-co-L-lactide), poly(L-lactide-co-glycolide), poly(D,L-lactide-co-glycolide) (PDLLAGA), poly(L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone), poly(hydroxyvalerate), polycaprolactone, poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), polycyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), polyurethanes, polyphosphazenes, silicones, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, acrylic polymers and copolymers, vinyl halide polymers and copolymers, such as polyvinyl chloride, polyvinyl ethers, such as polyvinyl methyl ether, polyvinylidene halides, fluoro polymers or copolymers under the trade name Solef™ or Kynar™ such as polyvinylidene fluoride (PVDF) and poly(vinylidene fluoride-co-hexafluoropropylene), polyvinylidene chloride, poly(butyl methacrylate), polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics, such as polystyrene, polyvinyl esters, such as polyvinyl acetate, copolymers of vinyl monomers with each other and olefins, such as ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, isobutylene-styrene copolymers, methacrylate-styrene copolymer, ABS resins, and ethylene-vinyl acetate copolymers, polyamides, such as Nylon 66 and polycaprolactam, alkyd resins, polycarbonates, polyoxymethylenes, polyimides, polyethers, polyvinylpyrrolidone (PVP), poly(vinyl alcohol) (PVA), polyacrylamide (PAAm), poly(glyceryl sebacate), poly(propylene fumarate), epoxy resins, polyurethanes, rayon, rayon-triacetate, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, and carboxymethyl cellulose.

[0024] The biocompatible polymer can provide a controlled release of a bioactive agent, if included in the coating and/or binding the bioactive agent to a substrate, which can be the surface of a medical device or a coating thereon. Controlled release and delivery of bioactive agent using a polymeric carrier has been extensively researched in the past several decades (see, for example, Mathiowitz, Ed., Encyclopedia of Controlled Drug Delivery, C.H.I.P.S., 1999). For example, PLA based drug delivery systems have provided controlled release of many therapeutic drugs with various degrees of success (see, for example, U.S. Pat. No. 5,581,387 to Labrie, et al.). The release rate of the bioactive agent can be controlled by, for example, by selection of a particular type of biocompatible polymer which can provide a desired release profile of the bioactive agent. The release profile of the bioactive agent can be further controlled by the molecular weight of the biocompatible polymer and/or the ratio of the biocompatible polymer over the bioactive agent. In the case of a biodegradable polymer, the release profile can also be controlled by the degradation rate of the biodegradable polymer. One of ordinary skill in the art can readily select a carrier system using a biocompatible polymer to provide a controlled release of the bioactive agent.

[0025] A preferred biocompatible polymer is a polyester, such as one of poly(ester amide), poly(D,L-lactide) (PDLLA), poly(D,L-lactic acid-co-glycolic acid) (PDLLGA), polyglycolic acid (PGA), polyhydroxyalkanoate (PHA), poly(3-hydroxybutyrate) (PHB), poly(3-hydroxybutyrate-co-3-hydroxyvalerate), poly((3-hydroxyvalerate), poly(3-hydroxyhexanoate), poly(4-hydroxybutyrate), poly(4-hydroxyvalerate), poly(4-hydroxyhexanoate), poly(D,L-lactide), poly(L-lactide), polycaprolactone (PCL) and a combination thereof.

[0026] The biobeneficial material can be a polymeric material or non-polymeric material. The biobeneficial material is preferably flexible when present as a discrete layer, or confers elastic properties in a blend or copolymer, and is biocompatible and/or biodegradable, more preferably non-toxic, non-antigenic and non-immunogenic. A biobeneficial material is one which enhances the biocompatibility of a device by being non-fouling, hemocompatible, actively non-thrombogenic, or anti-inflammatory, all without depending on the release of a pharmaceutically active agent. As used herein, the term non-fouling is defined as preventing, delaying or reducing the amount of formation of protein build-up caused by the body's reaction to foreign material and can be used interchangeably with the term “anti-fouling.”

[0027] Representative biobeneficial materials include, but are not limited to, polyethers such as poly(ethylene glycol), copoly(ether-esters) (e.g. PEO/PLA); polyalkylene oxides such as poly(ethylene oxide), poly(propylene oxide), poly(ether ester), polyalkylene oxalates, polyphosphazenes, phosphoryl choline, choline, poly(aspirin), polymers and co-polymers of hydroxyl bearing monomers such as hydroxyethyl methacrylate (HEMA), hydroxypropyl methacrylate (HPMA), hydroxypropyl methacrylamide, PEG acrylate (PEGA), PEG methacrylate, 2-methacryloyloxyethylphosphorylcholine (MPC) and n-vinyl pyrrolidone (VP), carboxylic acid bearing monomers such as methacrylic acid (MA), acrylic acid (AA), alkoxymethacrylate, alkoxyacrylate, and 3-trimethylsilylpropyl methacrylate (TMSPMA), polystyrene-polyisoprene-polystyrene-co-PEG (SIS-PEG), polystyrene-PEG, polyisobutylene-PEG, polycaprolactone-PEG (PCL-PEG), PLA-PEG, poly(methyl methacrylate)-PEG (PMMA-PEG), polydimethylsiloxane-co-PEG (PDMS-PEG), poly(vinylidene fluoride)-PEG (PVDF-PEG), PLURONIC™ surfactants (polypropylene oxide-co-polyethylene glycol), poly(tetramethylene glycol), hydroxy functional poly(vinyl pyrrolidone), biomolecules such as fibrin, fibrinogen, cellulose, starch, collagen, dextran, dextrin, hyaluronic acid, fragments and derivatives of hyaluronic acid, heparin, fragments and derivatives of heparin, glycosamino glycan (GAG), GAG derivatives, polysaccharide, elastin, chitosan, alginate, silicones, and combinations thereof. In some embodiments, the biobeneficial material can exclude any one of the aforementioned materials.

[0028] In a preferred embodiment, the biobeneficial material is a block copolymer comprising flexible poly(ethylene glycol terephthalate)/poly(butylenes terephthalate) (PEGT/PBT) segments (PolyActive™). These segments are biocompatible, non-toxic, non-antigenic and non-immunogenic. Previous studies have shown that the PolyActive™ top coat decreases the thrombosis and embolism formation on stents. PolyActive™ is generally expressed in the form of xPEGTyPBTz, in which x is the molecular weight of PEG, y is percentage of PEGT, and z is the percentage of PBT. A specific PolyActive™ polymer can have various ratios of the PEG, ranging from about 1% to about 99%, e.g., about 10% to about 90%, about 20% to about 80%, about 30% to about 70%, about 40% to about 60% PEG. The PEG for forming PolyActive™ can have a molecular weight ranging from about 300 Daltons to about 100,000 Daltons, e.g., about 300 Daltons, about 500 Daltons, about 1,000 Daltons, about 5,000 Daltons, about 10,000 Daltons, about 20,000 Daltons, or about 50,000 Daltons.

[0029] In another preferred embodiment, the biobeneficial material can be a polyether such as polyethylene glycol (PEG) or polyalkylene oxide.

[0030] The bioactive agents can be any diagnostic, preventive and therapeutic agents. Examples of such agents include synthetic inorganic and organic compounds, proteins and peptides, polysaccharides and other sugars, lipids, and DNA and RNA nucleic acid sequences having therapeutic, prophylactic or diagnostic activities. Nucleic acid sequences include genes, antisense molecules which bind to complementary DNA to inhibit transcription, and ribozymes. Other examples of drugs include antibodies, receptor ligands, and enzymes, adhesion peptides, oligosaccharides, blood clotting factors, inhibitors or clot dissolving agents such as streptokinase and tissue plasminogen activator, antigens for immunization, hormones and growth factors, oligonucleotides such as antisense oligonucleotides and ribozymes and retroviral vectors for use in gene therapy. Such agents can also include a prohealing drug that imparts a benign neointimal response characterized by controlled proliferation of smooth muscle cells and controlled deposition of extracellular matrix with complete luminal coverage by phenotypically functional (similar to uninjured, healthy intima) and morphologically normal (similar to uninjured, healthy intima) endothelial cells. Such agents can also fall under the genus of antineoplastic, cytostatic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant substances. Examples of such antineoplastics and/or antimitotics include paclitaxel (e.g. TAXOL® by Bristol-Myers Squibb Co., Stamford, Conn.), docetaxel (e.g. Taxotere®, from Aventis S.A., Frankfurt, Germany) methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g. Adriamycin® from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g. Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.). Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include heparinoids, hirudin, recombinant hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist, antibody, and thrombin inhibitors such as Angiomax ä (Biogen, Inc., Cambridge, Mass.). Examples of cytostatic agents include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capotene® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g. Prinivil® and Prinzide® from Merck & Co., Inc., Whitehouse Station, N.J.), actinomycin D, or derivatives and analogs thereof (manufactured by Sigma-Aldrich 1001 West Saint Paul Avenue, Milwaukee, Wis. 53233; or COSMEGEN available from Merck). Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin I₁, actinomycin X₁, and actinomycin C₁. Other drugs include calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. An example of an antiallergic agent is permirolast potassium.

[0031] Other therapeutic substances or agents which may be appropriate include alpha-interferon, genetically engineered epithelial cells, bioactive RGD, antibodies such as CD-34 antibody, abciximab (REOPRO), and progenitor cell capturing antibody, prohealing drugs that promotes controlled proliferation of muscle cells with a normal and physiologically benign composition and synthesis products, enzymes, antivirals, anticancer drugs, anticoagulant agents, free radical scavengers, steroidal anti-inflammatory agents, non-steroidal anti-inflammatory agents, antibiotics, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), dexamethasone, clobetasol, aspirin, estradiol, tacrolimus, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), pimecrolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, progenitor cell capturing antibody, pro-drugs thereof, co-drugs thereof, and a combination thereof. The foregoing substances are listed by way of example and are not meant to be limiting. Other active agents which are currently available or that may be developed in the future are equally applicable.

Examples of Medical Device

[0032] As used herein, a medical device may be any suitable medical substrate that can be implanted in a human or veterinary patient. Examples of such medical devices include self-expandable stents, balloon-expandable stents, stent-grafts, grafts (e.g., aortic grafts), artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation, Santa Clara, Calif.). The underlying structures can be of virtually any design. The device can be made of a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), high nitrogen stainless steel, e.g., BIODUR 108, cobalt chrome alloy L-605, “MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof. “MP35N” and “MP20N” are trade names for alloys of cobalt, nickel, chromium and molybdenum available from Standard Press Steel Co., Jenkintown, Pa. “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. “MP20N” consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum. Devices made from bioabsorbable or biostable polymers could also be used with the embodiments of the present invention. For example, the device can be a bioabsorbable stent, made from a polymeric material (and optionally erodable metal). The bioabsorbable stent can include a drug coating, for example with a polymer film layer or the drug can be compounded or embedded in the body of the stent.

Method of Use

[0033] A medical device (e.g., stent) having any of the above-described features is useful for a variety of medical procedures, including, by way of example, treatment of obstructions caused by tumors in bile ducts, esophagus, trachea/bronchi and other biological passageways. A stent having the above-described coating is particularly useful for treating occluded regions of blood vessels caused by abnormal or inappropriate migration and proliferation of smooth muscle cells, thrombosis, restenosis, and vulnerable plaque. Stents may be placed in a wide array of blood vessels, both arteries and veins. Representative examples of sites include the iliac, renal, and coronary arteries.

[0034] For implantation of a stent, an angiogram is first performed to determine the appropriate positioning for stent therapy. An angiogram is typically accomplished by injecting a radiopaque contrasting agent through a catheter inserted into an artery or vein as an x-ray is taken. A guidewire is then advanced through the lesion or proposed site of treatment. Over the guidewire is passed a delivery catheter which allows a stent in its collapsed configuration to be inserted into the passageway. The delivery catheter is inserted either percutaneously or by surgery into the femoral artery, brachial artery, femoral vein, or brachial vein, and advanced into the appropriate blood vessel by steering the catheter through the vascular system under fluoroscopic guidance. A stent having with or without a drug delivery coating may then be expanded at the desired area of treatment. A post-insertion angiogram may also be utilized to confirm appropriate positioning.

Example

Study of BHT Loss in the Stent Manufacture Process

Experiment Results and Discussion

Table 2 listed sampling schemes for the tested sample stents.

[0035]

TABLE 2

Sampling scheme
		# of stent	# of stent
Stent		for BHT	for drug
Label	Sampling steps	test	content

1	After stent secured on the balloon	5	4
	and packaged in Tyvek pouch
2	After ETO sterilization	5	4

Besides the sampling scheme for stents, BHT amount in the drug substance and in the coating solution was also assayed. The stents were manufactured by following standard Guidant procedures, which included drug coat solution mixing, spray coating, drying, stent retention on the balloon catheters, and packaging of coated stent device in Tvyek pouch.

[0036] Table 3 is a summary of BHT and total content of the drug (TC) test results at the various stages of stent manufacture process.

[0037]

TABLE 3

Summary of BHT and TC test results
			BHT found,	% BHT	% BHT
Groups	Conditions	TC, %	ng/ug drug	retained	loss

	Raw drug		1.78	100	0
	Drug coat solution		1.80	101.1	0
1	before ETO	98.5	0.97	54.6	45.4
2	Post ETO	94.8	0.11	5.9	94.1

The percent BHT was normalized based on BHT in raw drug substance. The results showed that the drug mixing process did not change BHT content. About 45% BHT was lost during stent spray coating, drying and stent retention process. With conventional ETO process, BHT dropped from ˜50% to ˜5% before and after ETO. Total content recovery was correlated with BHT level. The higher the BHT amount in the stents, the higher the total content recovery of the drug, indicating missing total content of the drug might be related to oxidation of the drug.

[0038] Since BHT loss in ETO process was severe, a study was designed to determine the cause. 100 mg of BHT was weighed in an aluminum pan and baked in a convectional oven at 55° C. and checked at 1 hr and 16 hr. The pan was weighed after each time point. After overnight baking, all the BHT powder was gone. The experiment was repeated at 70° C. for 30 minutes and 1 hr. Since 70° C. is the melting temperature for BHT, the results represented the worst case. The experiment was redone at 40° C. and 50° C. for 1 hr, 4 h, 7 h and 24 h. FIG. 4 is the plot of BHT weight loss vs. time at various temperatures. As shown in FIG. 4, it is clear that BHT sublimation occurred at temperatures under 70° C. FIG. 5 is a plot of Ln (BHT/BHT₀) vs. time. Linearity was seen at 40° C. and 50° C. baking, indicating first order sublimation kinetics. No curve fitting was performed on 55° C. and 70° C. experiment conditions, due to not enough data points. Equation 1 represents 1^storder kinetics,

[0039]

\begin{matrix} Ln \frac{BHT}{{BHT}_{0}} = - kt & (1) \end{matrix}

where BHT/BHT₀is the ratio of BHT remained in the pan at time t and k is the sublimation rate constant at the experiment temperature. Using equation 1, the half-lives for BHT sublimation are ˜13 hr at 40° C. and ˜5 hr at 50° C.

[0040] Based on the curve fitting in FIG. 5, k_40C=0.048 and k_50C=0.1331. Using Arrhenius equation (Equation 2),

[0041]

\begin{matrix} Ln \frac{k_{2}}{k_{1}} = \frac{E_{a}}{R} [\frac{T_{2} - T_{1}}{T_{1} T_{2}}] & (2) \end{matrix}

where R is the gas constant (1.987) and E_ais the sublimation activation energy, the activation energy for BHT sublimation is 20.5 kcal/mol. The rate constant at other temperatures can be readily calculated with equations 1 and 2.

[0042] The sublimation energy for BHT is about 2 times of water's heat of vaporization, which is not very high. The experiment explained why BHT got lost during ETO process. Long time exposure of stents at 55° C. during ETO process can cause sublimation of BHT. With polymer protection, the sublimation rate was largely reduced.

[0043] The study showed that ETO process contributed heavily on BHT loss. It also demonstrated the relationship between total content recovery and BHT levels on the stent. The study also demonstrated that one could take advantage of the volatile nature of BHT and BHA to enhance the product performance by placing or coating BHT/BHA in the secondary package. Other benefits include increase in storage life of the product.

[0044] While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects. Therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.

Claims

What is claimed is:

1. A method of providing a volatile antioxidant to a medical device having a drug for local delivery of the drug, comprising adding the volatile antioxidant to the medical device having the drug,

wherein adding comprises providing the volatile antioxidant in the proximity or surrounding of the medical device thereby allowing the antioxidant to permeate into the medical device and/or a coating on the medical device,

wherein the adding comprises

(a) placing an amount of the volatile antioxidant in a porous or permeable container within the packaging of the drug delivery medical device; followed by

(b) subjecting the device to ethylene oxide sterilization;

wherein the medical device is outside of the container.

2. The method of claim 1, wherein the medical device or the drug includes a second antioxidant, the second antioxidant being the same as or different than the volatile antioxidant, such that the volatile antioxidant is added subsequent to a loss of the second antioxidant from the medical device.

3. The method of claim 1, wherein the volatile antioxidant is added to a coating on the medical device.

4. The method of claim 1, wherein the medical device includes a coating having the drug and wherein the volatile antioxidant is added to the coating.

5. The method of claim 1, wherein the device is a stent.

6. The method of claim 1, wherein the volatile antioxidant comprises butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA) or a combination of both.

7. The method of claim 1, wherein the volatile antioxidant sublimates to form a gas.

8. The method of claim 1, wherein the medical device does not include an antioxidant prior to addition of the volatile antioxidant.

9. The method of claim 2, wherein the volatile antioxidant is added to compensate for the whole or partial loss of the second antioxidant from the medical device.

10. The method of claim 2, wherein the volatile antioxidant is added in an amount more than the loss of the second antioxidant from the medical device.

11. A method of packing a drug delivery medical device, comprising,

(a) inserting a drug delivery medical device in a packaging; and

(b) placing an amount of a volatile antioxidant in a porous or permeable container within the packaging;

wherein the medical device is outside of the container.

12. The method of claim 11, additionally comprising sterilizing the device subsequent to the placement of the volatile antioxidant in the packaging.

13. The method of claim 11, wherein the drug delivery medical device comprises a stent.

14. The method of claim 11, wherein the drug delivery medical device comprises a coated stent, wherein the coating includes the drug.

15. The method of claim 11, wherein the volatile antioxidant comprises butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA) or a combination of both.

16. The method of claim 11, additionally comprising causing sublimation of the volatile antioxidant by a sterilization procedure, by exposure to heat, or a combination of both.

Patent Citations (401)

Patent	Date	Inventor	Cited By
US2072303(A)	1937-03-01	Hermann et al.	Applicant
US2386454(A)	1945-10-01	Frosch et al.	Applicant
US3429717(A)	1969-02-01	Cook	Examiner
US3773737(A)	1973-11-01	Goodman et al.	Applicant
US3849514(A)	1974-11-01	Gray, Jr. et al.	Applicant
US4226243(A)	1980-10-01	Shalaby et al.	Applicant
US4329383(A)	1982-05-01	Joh	Applicant
US4343931(A)	1982-08-01	Barrows	Applicant
US4529792(A)	1985-07-01	Barrows	Applicant
US4611051(A)	1986-09-01	Hayes et al.	Applicant
US4656242(A)	1987-04-01	Swan et al.	Applicant
US4733665(A)	1988-03-01	Palmaz	Applicant
US4800882(A)	1989-01-01	Gianturco	Applicant
US4882168(A)	1989-11-01	Casey et al.	Applicant
US4886062(A)	1989-12-01	Wiktor	Applicant
US4931287(A)	1990-06-01	Bae et al.	Applicant
US4941870(A)	1990-07-01	Okada et al.	Applicant
US4977901(A)	1990-12-01	Ofstead	Applicant
US5019096(A)	1991-05-01	Fox, Jr. et al.	Applicant
US5100992(A)	1992-03-01	Cohn et al.	Applicant
US5112457(A)	1992-05-01	Marchant	Applicant
US5133742(A)	1992-07-01	Pinchuk	Applicant
US5163952(A)	1992-11-01	Froix	Applicant
US5165919(A)	1992-11-01	Sasaki et al.	Applicant
US5219980(A)	1993-06-01	Swidler	Applicant
US5258020(A)	1993-11-01	Froix	Applicant
US5272012(A)	1993-12-01	Opolski	Applicant
US5292516(A)	1994-03-01	Viegas et al.	Applicant
US5298260(A)	1994-03-01	Viegas et al.	Applicant
US5300295(A)	1994-04-01	Viegas et al.	Applicant
US5306501(A)	1994-04-01	Viegas et al.	Applicant
US5306786(A)	1994-04-01	Moens et al.	Applicant
US5328471(A)	1994-07-01	Slepian	Applicant
US5330768(A)	1994-07-01	Park et al.	Applicant
US5380299(A)	1995-01-01	Fearnot et al.	Applicant
US5417981(A)	1995-05-01	Endo et al.	Applicant
US5447724(A)	1995-09-01	Helmus et al.	Applicant
US5455040(A)	1995-10-01	Marchant	Applicant
US5462990(A)	1995-10-01	Hubbell et al.	Applicant
US5464650(A)	1995-11-01	Berg et al.	Applicant
US5485496(A)	1996-01-01	Lee et al.	Applicant
US5516881(A)	1996-05-01	Lee et al.	Applicant
US5569463(A)	1996-10-01	Helmus et al.	Applicant
US5578073(A)	1996-11-01	Haimovich et al.	Applicant
US5584877(A)	1996-12-01	Miyake et al.	Applicant
US5605696(A)	1997-02-01	Eury et al.	Applicant
US5607467(A)	1997-03-01	Froix	Applicant
US5609629(A)	1997-03-01	Fearnot et al.	Applicant
US5610241(A)	1997-03-01	Lee et al.	Applicant
US5616338(A)	1997-04-01	Fox, Jr. et al.	Applicant
US5624411(A)	1997-04-01	Tuch	Applicant
US5628730(A)	1997-05-01	Shapland et al.	Applicant
US5644020(A)	1997-07-01	Timmermann et al.	Applicant
US5649977(A)	1997-07-01	Campbell	Applicant
US5658995(A)	1997-08-01	Kohn et al.	Applicant
US5667767(A)	1997-09-01	Greff et al.	Applicant
US5670558(A)	1997-09-01	Onishi et al.	Applicant
US5674242(A)	1997-10-01	Phan et al.	Applicant
US5679400(A)	1997-10-01	Tuch	Applicant
US5700286(A)	1997-12-01	Tartaglia et al.	Applicant
US5702754(A)	1997-12-01	Zhong	Applicant
US5711958(A)	1998-01-01	Cohn et al.	Applicant
US5716981(A)	1998-02-01	Hunter et al.	Applicant
US5721131(A)	1998-02-01	Rudolph et al.	Applicant
US5723219(A)	1998-03-01	Kolluri et al.	Applicant
US5735897(A)	1998-04-01	Buirge	Applicant
US5746998(A)	1998-05-01	Torchilin et al.	Applicant
US5759205(A)	1998-06-01	Valentini	Applicant
US5776184(A)	1998-07-01	Tuch	Applicant
US5783657(A)	1998-07-01	Pavlin et al.	Applicant
US5788979(A)	1998-08-01	Alt et al.	Applicant
US5800392(A)	1998-09-01	Racchini	Applicant
US5820917(A)	1998-10-01	Tuch	Applicant
US5824048(A)	1998-10-01	Tuch	Applicant
US5824049(A)	1998-10-01	Ragheb et al.	Applicant
US5830178(A)	1998-11-01	Jones et al.	Applicant
US5837008(A)	1998-11-01	Berg et al.	Applicant
US5837313(A)	1998-11-01	Ding et al.	Applicant
US5849859(A)	1998-12-01	Acemoglu	Applicant
US5851508(A)	1998-12-01	Greff et al.	Applicant
US5854376(A)	1998-12-01	Higashi	Applicant
US5857998(A)	1999-01-01	Barry	Applicant
US5858746(A)	1999-01-01	Hubbell et al.	Applicant
US5865814(A)	1999-02-01	Tuch	Applicant
US5869127(A)	1999-02-01	Zhong	Applicant
US5873904(A)	1999-02-01	Ragheb et al.	Applicant
US5876433(A)	1999-03-01	Lunn	Applicant
US5877224(A)	1999-03-01	Brocchini et al.	Applicant
US5879713(A)	1999-03-01	Roth et al.	Applicant
US5902875(A)	1999-05-01	Roby et al.	Applicant
US5905168(A)	1999-05-01	Dos Santos et al.	Applicant
US5910564(A)	1999-06-01	Gruning et al.	Applicant
US5914387(A)	1999-06-01	Roby et al.	Applicant
US5919893(A)	1999-07-01	Roby et al.	Applicant
US5925720(A)	1999-07-01	Kataoka et al.	Applicant
US5932299(A)	1999-08-01	Katoot	Applicant
US5955509(A)	1999-09-01	Webber et al.	Applicant
US5958385(A)	1999-09-01	Tondeur et al.	Applicant
US5962138(A)	1999-10-01	Kolluri et al.	Applicant
US5971954(A)	1999-10-01	Conway et al.	Applicant
US5980928(A)	1999-11-01	Terry	Applicant
US5980972(A)	1999-11-01	Ding	Applicant
US5997517(A)	1999-12-01	Whitbourne	Applicant
US6010530(A)	2000-01-01	Goicoechea	Applicant
US6011125(A)	2000-01-01	Lohmeijer et al.	Applicant
US6015541(A)	2000-01-01	Greff et al.	Applicant
US6033582(A)	2000-03-01	Lee et al.	Applicant
US6034204(A)	2000-03-01	Mohr et al.	Applicant
US6037022(A)	2000-03-01	Adur et al.	Examiner
US6042875(A)	2000-03-01	Ding et al.	Applicant
US6051576(A)	2000-04-01	Ashton et al.	Applicant
US6051648(A)	2000-04-01	Rhee et al.	Applicant
US6054553(A)	2000-04-01	Groth et al.	Applicant
US6056993(A)	2000-05-01	Leidner et al.	Applicant
US6060451(A)	2000-05-01	DiMaio et al.	Applicant
US6060518(A)	2000-05-01	Kabanov et al.	Applicant
US6080488(A)	2000-06-01	Hostettler et al.	Applicant
US6096070(A)	2000-08-01	Ragheb et al.	Applicant
US6099562(A)	2000-08-01	Ding et al.	Applicant
US6110188(A)	2000-08-01	Narciso, Jr.	Applicant
US6110483(A)	2000-08-01	Whitbourne et al.	Applicant
US6113629(A)	2000-09-01	Ken	Applicant
US6120491(A)	2000-09-01	Kohn et al.	Applicant
US6120536(A)	2000-09-01	Ding et al.	Applicant
US6120788(A)	2000-09-01	Barrows	Applicant
US6120904(A)	2000-09-01	Hostettler et al.	Applicant
US6121027(A)	2000-09-01	Clapper et al.	Applicant
US6129761(A)	2000-10-01	Hubbell	Applicant
US6136333(A)	2000-10-01	Cohn et al.	Applicant
US6143354(A)	2000-11-01	Koulik et al.	Applicant
US6153252(A)	2000-11-01	Hossainy et al.	Applicant
US6159978(A)	2000-12-01	Myers et al.	Applicant
US6165212(A)	2000-12-01	Dereume et al.	Applicant
US6172167(B1)	2001-01-01	Stapert et al.	Applicant
US6177523(B1)	2001-01-01	Reich et al.	Applicant
US6180632(B1)	2001-01-01	Myers et al.	Applicant
US6203551(B1)	2001-03-01	Wu	Applicant
US6211249(B1)	2001-04-01	Cohn et al.	Applicant
US6214901(B1)	2001-04-01	Chudzik et al.	Applicant
US6231600(B1)	2001-05-01	Zhong	Applicant
US6240616(B1)	2001-06-01	Yan	Applicant
US6245753(B1)	2001-06-01	Byun et al.	Applicant
US6245760(B1)	2001-06-01	He et al.	Applicant
US6248129(B1)	2001-06-01	Froix	Applicant
US6251136(B1)	2001-06-01	Guruwaiya et al.	Applicant
US6254632(B1)	2001-07-01	Wu et al.	Applicant
US6258121(B1)	2001-07-01	Yang et al.	Applicant
US6258371(B1)	2001-07-01	Koulik et al.	Applicant
US6262034(B1)	2001-07-01	Mathiowitz et al.	Applicant
US6270788(B1)	2001-08-01	Koulik et al.	Applicant
US6277449(B1)	2001-08-01	Kolluri et al.	Applicant
US6283947(B1)	2001-09-01	Mirzaee	Applicant
US6283949(B1)	2001-09-01	Roorda	Applicant
US6284305(B1)	2001-09-01	Ding et al.	Applicant
US6287628(B1)	2001-09-01	Hossainy et al.	Applicant
US6299604(B1)	2001-10-01	Ragheb et al.	Applicant
US6306176(B1)	2001-10-01	Whitbourne	Applicant
US6331313(B1)	2001-12-01	Wong et al.	Applicant
US6335029(B1)	2002-01-01	Kamath et al.	Applicant
US6344035(B1)	2002-02-01	Chudzik et al.	Applicant
US6346110(B2)	2002-02-01	Wu	Applicant
US6358556(B1)	2002-03-01	Ding et al.	Applicant
US6379381(B1)	2002-04-01	Hossainy et al.	Applicant
US6387379(B1)	2002-05-01	Goldberg et al.	Applicant
US6395326(B1)	2002-05-01	Castro et al.	Applicant
US6419692(B1)	2002-07-01	Yang et al.	Applicant
US6451373(B1)	2002-09-01	Hossainy et al.	Applicant
US6482834(B2)	2002-11-01	Spada et al.	Applicant
US6494862(B1)	2002-12-01	Ray et al.	Applicant
US6503538(B1)	2003-01-01	Chu et al.	Applicant
US6503556(B2)	2003-01-01	Harish et al.	Applicant
US6503954(B1)	2003-01-01	Bhat et al.	Applicant
US6506437(B1)	2003-01-01	Harish et al.	Applicant
US6524347(B1)	2003-02-01	Myers et al.	Applicant
US6527801(B1)	2003-03-01	Dutta	Applicant
US6527863(B1)	2003-03-01	Pacetti et al.	Applicant
US6528526(B1)	2003-03-01	Myers et al.	Applicant
US6530950(B1)	2003-03-01	Alvarado et al.	Applicant
US6530951(B1)	2003-03-01	Bates et al.	Applicant
US6540776(B2)	2003-04-01	Sanders Millare et al.	Applicant
US6544223(B1)	2003-04-01	Kokish	Applicant
US6544543(B1)	2003-04-01	Mandrusov et al.	Applicant
US6544582(B1)	2003-04-01	Yoe	Applicant
US6555157(B1)	2003-04-01	Hossainy	Applicant
US6558733(B1)	2003-05-01	Hossainy et al.	Applicant
US6565659(B1)	2003-05-01	Pacetti et al.	Applicant
US6572644(B1)	2003-06-01	Moein	Applicant
US6585755(B2)	2003-07-01	Jackson et al.	Applicant
US6585765(B1)	2003-07-01	Hossainy et al.	Applicant
US6585926(B1)	2003-07-01	Mirzaee	Applicant
US6605154(B1)	2003-08-01	Villareal	Applicant
US6616765(B1)	2003-09-01	Hossainy et al.	Applicant
US6623448(B2)	2003-09-01	Slater	Applicant
US6625486(B2)	2003-09-01	Lundkvist et al.	Applicant
US6645135(B1)	2003-11-01	Bhat	Applicant
US6645195(B1)	2003-11-01	Bhat et al.	Applicant
US6656216(B1)	2003-12-01	Hossainy et al.	Applicant
US6656506(B1)	2003-12-01	Wu et al.	Applicant
US6660034(B1)	2003-12-01	Mandrusov et al.	Applicant
US6663662(B2)	2003-12-01	Pacetti et al.	Applicant
US6663880(B1)	2003-12-01	Roorda et al.	Applicant
US6666880(B1)	2003-12-01	Chiu et al.	Applicant
US6673154(B1)	2004-01-01	Pacetti et al.	Applicant
US6673385(B1)	2004-01-01	Ding et al.	Applicant
US6689099(B2)	2004-02-01	Mirzaee	Applicant
US6695920(B1)	2004-02-01	Pacetti et al.	Applicant
US6706013(B1)	2004-03-01	Bhat et al.	Applicant
US6709514(B1)	2004-03-01	Hossainy	Applicant
US6712845(B2)	2004-03-01	Hossainy	Applicant
US6713119(B2)	2004-03-01	Hossainy et al.	Applicant
US6716444(B1)	2004-04-01	Castro et al.	Applicant
US6723120(B2)	2004-04-01	Yan	Applicant
US6733768(B2)	2004-05-01	Hossainy et al.	Applicant
US6740040(B1)	2004-05-01	Mandrusov et al.	Applicant
US6743462(B1)	2004-06-01	Pacetti	Applicant
US6749626(B1)	2004-06-01	Bhat et al.	Applicant
US6753071(B1)	2004-06-01	Pacetti et al.	Applicant
US6758859(B1)	2004-07-01	Dang et al.	Applicant
US6759054(B2)	2004-07-01	Chen et al.	Applicant
US6764505(B1)	2004-07-01	Hossainy et al.	Applicant
US6861088(B2)	2005-03-01	Weber et al.	Applicant
US6865810(B2)	2005-03-01	Stinson	Applicant
US6869443(B2)	2005-03-01	Buscemi et al.	Applicant
US6878160(B2)	2005-04-01	Gilligan et al.	Applicant
US6887270(B2)	2005-05-01	Miller et al.	Applicant
US6887485(B2)	2005-05-01	Fitzhugh et al.	Applicant
US6890546(B2)	2005-05-01	Mollison et al.	Applicant
US6899731(B2)	2005-05-01	Li et al.	Applicant
US2001/0007083(A1)	2001-07-01	Roorda	Applicant
US2001/0014717(A1)	2001-08-01	Hossainy et al.	Applicant
US2001/0018469(A1)	2001-08-01	Chen et al.	Applicant
US2001/0020011(A1)	2001-09-01	Mathiowitz et al.	Applicant
US2001/0029351(A1)	2001-10-01	Falotico et al.	Applicant
US2001/0037145(A1)	2001-11-01	Guruwaiya et al.	Applicant
US2001/0051608(A1)	2001-12-01	Mathiowitz et al.	Applicant
US2002/0005206(A1)	2002-01-01	Falotico et al.	Applicant
US2002/0007213(A1)	2002-01-01	Falotico et al.	Applicant
US2002/0007214(A1)	2002-01-01	Falotico	Applicant
US2002/0007215(A1)	2002-01-01	Falotico et al.	Applicant
US2002/0009604(A1)	2002-01-01	Zamora et al.	Applicant
US2002/0016625(A1)	2002-02-01	Falotico et al.	Applicant
US2002/0032414(A1)	2002-03-01	Ragheb et al.	Applicant
US2002/0032434(A1)	2002-03-01	Chudzik et al.	Applicant
US2002/0051730(A1)	2002-05-01	Bodnar et al.	Applicant
US2002/0071822(A1)	2002-06-01	Uhrich	Applicant
US2002/0077693(A1)	2002-06-01	Barclay et al.	Applicant
US2002/0082679(A1)	2002-06-01	Sirhan et al.	Applicant
US2002/0087123(A1)	2002-07-01	Hossainy et al.	Applicant
US2002/0091433(A1)	2002-07-01	Ding et al.	Applicant
US2002/0094440(A1)	2002-07-01	Llanos et al.	Applicant
US2002/0111590(A1)	2002-08-01	Davila et al.	Applicant
US2002/0120326(A1)	2002-08-01	Michal	Applicant
US2002/0123801(A1)	2002-09-01	Pacetti et al.	Applicant
US2002/0142039(A1)	2002-10-01	Claude	Applicant
US2002/0153511(A1)	2002-10-01	Cotterman et al.	Examiner
US2002/0155212(A1)	2002-10-01	Hossainy	Applicant
US2002/0165608(A1)	2002-11-01	Llanos et al.	Applicant
US2002/0176849(A1)	2002-11-01	Slepian	Applicant
US2002/0183581(A1)	2002-12-01	Yoe et al.	Applicant
US2002/0188037(A1)	2002-12-01	Chudzik et al.	Applicant
US2002/0188277(A1)	2002-12-01	Roorda et al.	Applicant
US2003/0004141(A1)	2003-01-01	Brown	Applicant
US2003/0028243(A1)	2003-02-01	Bates et al.	Applicant
US2003/0028244(A1)	2003-02-01	Bates et al.	Applicant
US2003/0031780(A1)	2003-02-01	Chudzik et al.	Applicant
US2003/0032767(A1)	2003-02-01	Tada et al.	Applicant
US2003/0036794(A1)	2003-02-01	Ragheb et al.	Applicant
US2003/0039689(A1)	2003-02-01	Chen et al.	Applicant
US2003/0040712(A1)	2003-02-01	Ray et al.	Applicant
US2003/0040790(A1)	2003-02-01	Furst	Applicant
US2003/0059520(A1)	2003-03-01	Chen et al.	Applicant
US2003/0060877(A1)	2003-03-01	Falotico et al.	Applicant
US2003/0065377(A1)	2003-04-01	Davila et al.	Applicant
US2003/0072868(A1)	2003-04-01	Harish et al.	Applicant
US2003/0073961(A1)	2003-04-01	Happ	Applicant
US2003/0083646(A1)	2003-05-01	Sirhan et al.	Applicant
US2003/0083739(A1)	2003-05-01	Cafferata	Applicant
US2003/0097088(A1)	2003-05-01	Pacetti	Applicant
US2003/0097173(A1)	2003-05-01	Dutta	Applicant
US2003/0099712(A1)	2003-05-01	Jayaraman	Applicant
US2003/0105518(A1)	2003-06-01	Dutta	Applicant
US2003/0113439(A1)	2003-06-01	Pacetti et al.	Applicant
US2003/0150380(A1)	2003-08-01	Yoe	Applicant
US2003/0157241(A1)	2003-08-01	Hossainy et al.	Applicant
US2003/0158517(A1)	2003-08-01	Kokish	Applicant
US2003/0190406(A1)	2003-10-01	Hossainy et al.	Applicant
US2003/0204239(A1)	2003-10-01	Carlyle et al.	Applicant
US2003/0207020(A1)	2003-11-01	Villareal	Applicant
US2003/0211230(A1)	2003-11-01	Pacetti et al.	Applicant
US2004/0018296(A1)	2004-01-01	Castro et al.	Applicant
US2004/0029952(A1)	2004-02-01	Chen et al.	Applicant
US2004/0047978(A1)	2004-03-01	Hossainy et al.	Applicant
US2004/0047980(A1)	2004-03-01	Pacetti et al.	Applicant
US2004/0052858(A1)	2004-03-01	Wu et al.	Applicant
US2004/0052859(A1)	2004-03-01	Wu et al.	Applicant
US2004/0054104(A1)	2004-03-01	Pacetti	Applicant
US2004/0060508(A1)	2004-04-01	Pacetti et al.	Applicant
US2004/0062853(A1)	2004-04-01	Pacetti et al.	Applicant
US2004/0063805(A1)	2004-04-01	Pacetti et al.	Applicant
US2004/0071861(A1)	2004-04-01	Mandrusov et al.	Applicant
US2004/0072922(A1)	2004-04-01	Hossainy et al.	Applicant
US2004/0073298(A1)	2004-04-01	Hossainy	Applicant
US2004/0086542(A1)	2004-05-01	Hossainy et al.	Applicant
US2004/0086550(A1)	2004-05-01	Roorda et al.	Applicant
US2004/0096504(A1)	2004-05-01	Michal	Applicant
US2004/0098117(A1)	2004-05-01	Hossainy et al.	Applicant
US2005/0004663(A1)	2005-01-01	Llanos et al.	Examiner
US2005/0037052(A1)	2005-02-01	Udipi et al.	Applicant
US2005/0038134(A1)	2005-02-01	Loomis et al.	Applicant
US2005/0038497(A1)	2005-02-01	Neuendorf et al.	Applicant
US2005/0043786(A1)	2005-02-01	Chu et al.	Applicant
US2005/0049693(A1)	2005-03-01	Walker	Applicant
US2005/0049694(A1)	2005-03-01	Neary	Applicant
US2005/0054774(A1)	2005-03-01	Kangas	Applicant
US2005/0055044(A1)	2005-03-01	Kangas	Applicant
US2005/0055078(A1)	2005-03-01	Campbell	Applicant
US2005/0060020(A1)	2005-03-01	Jenson	Applicant
US2005/0064088(A1)	2005-03-01	Fredrickson	Applicant
US2005/0065501(A1)	2005-03-01	Wallace	Applicant
US2005/0065545(A1)	2005-03-01	Wallace	Applicant
US2005/0065593(A1)	2005-03-01	Chu et al.	Applicant
US2005/0074406(A1)	2005-04-01	Couvillon, Jr. et al.	Applicant
US2005/0074545(A1)	2005-04-01	Thomas	Applicant
US2005/0075714(A1)	2005-04-01	Cheng et al.	Applicant
US2005/0079274(A1)	2005-04-01	Palasis et al.	Applicant
US2005/0084515(A1)	2005-04-01	Udipi et al.	Applicant
US2005/0106210(A1)	2005-05-01	Ding et al.	Applicant
US2005/0113903(A1)	2005-05-01	Rosenthal et al.	Applicant
DE4224401	1994-01-01		Applicant
EP301856	1989-02-01		Applicant
EP396429	1990-11-01		Applicant
EP514406	1992-11-01		Applicant
EP604022	1994-06-01		Applicant
EP623354	1994-11-01		Applicant
EP665023	1995-08-01		Applicant
EP701802	1996-03-01		Applicant
EP716836	1996-06-01		Applicant
EP809999	1997-12-01		Applicant
EP832655	1998-04-01		Applicant
EP850651	1998-07-01		Applicant
EP879595	1998-11-01		Applicant
EP910584	1999-04-01		Applicant
EP923953	1999-06-01		Applicant
EP953320	1999-11-01		Applicant
EP970711	2000-01-01		Applicant
EP982041	2000-03-01		Applicant
EP1023879	2000-08-01		Applicant
EP1192957	2002-04-01		Applicant
EP1273314	2003-01-01		Applicant
JP2001-190687	2001-07-01		Applicant
SU872531	1981-10-01		Applicant
SU876663	1981-10-01		Applicant
SU905228	1982-02-01		Applicant
SU790725	1983-02-01		Applicant
SU1016314	1983-05-01		Applicant
SU811750	1983-09-01		Applicant
SU1293518	1987-02-01		Applicant
WO91/12846	1991-09-01		Applicant
WO94/09760	1994-05-01		Applicant
WO95/10989	1995-04-01		Applicant
WO95/24929	1995-09-01		Applicant
WO96/40174	1996-12-01		Applicant
WO97/10011	1997-03-01		Applicant
WO97/45105	1997-12-01		Applicant
WO97/46590	1997-12-01		Applicant
WO98/08463	1998-03-01		Applicant
WO98/17331	1998-04-01		Applicant
WO98/32398	1998-07-01		Applicant
WO98/36784	1998-08-01		Applicant
WO99/01118	1999-01-01		Applicant
WO99/38546	1999-08-01		Applicant
WO99/63981	1999-12-01		Applicant
WO/02599	2000-01-01		Applicant
WO/12147	2000-03-01		Applicant
WO/18446	2000-04-01		Applicant
WO/64506	2000-11-01		Applicant
WO1/01890	2001-01-01		Applicant
WO1/15751	2001-03-01		Applicant
WO1/17577	2001-03-01		Applicant
WO1/45763	2001-06-01		Applicant
WO1/49338	2001-07-01		Applicant
WO1/51027	2001-07-01		Applicant
WO1/74414	2001-10-01		Applicant
WO1/90202	2001-11-01		Applicant
WO2/03890	2002-01-01		Applicant
WO2/26162	2002-04-01		Applicant
WO2/34311	2002-05-01		Applicant
WO2/056790	2002-07-01		Applicant
WO2/058753	2002-08-01		Applicant
WO2/102283	2002-12-01		Applicant
WO3/000308	2003-01-01		Applicant
WO3/022323	2003-03-01		Applicant
WO3/028780	2003-04-01		Applicant
WO3/037223	2003-05-01		Applicant
WO3/039612	2003-05-01		Applicant
WO3/053171	2003-07-01		Applicant
WO3/080147	2003-10-01		Applicant
WO3/082368	2003-10-01		Applicant
WO2004/000383	2003-12-01		Applicant
WO2004/009145	2004-01-01		Applicant
WO2005/016399	2005-02-01		Applicant

Non-Patent Literature (34)

International Search Report for PCT/US2006/027050, mailed Apr. 16, 2007, 9 pgs.Applicant
Anonymous, Cardiologists Draw—Up The Dream Stent, Clinica 710:15 (Jun. 17, 1996), http://www.dialogweb.com/cgi/document?req=1061848202959, printed Aug. 25, 2003 (2 pages).Applicant
Anonymous, Heparin-coated stents cut complications by 30%, Clinica 732:17 (Nov. 18, 1996), http://www.dialogweb.com/cgi/document?req=1061847871753, printed Aug. 25, 2003 (2 pages).Applicant
Anonymous, Rolling Therapeutic Agent Loading Device for Therapeutic Agent Delivery or Coated Stent (Abstract 434009), Res. Disclos. pp. 974-975 (Jun. 2000).Applicant
Anonymous, Stenting continues to dominate cardiology, Clinica 720:22 (Sep. 2, 1996), http://www.dialogweb.com/cgi/document?req=1061848017752, printed Aug. 25, 2003 (2 pages).Applicant
Aoyagi et al., Preparation of cross-linked aliphatic polyester and application to thermo-responsive material, Journal of Controlled Release 32:87-96 (1994).Applicant
Barath et al., Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury, JACC 13(2): 252A (Abstract) (Feb. 1989).Applicant
Barbucci et al., Coating of commercially available materials with a new heparinizable material, J. Biomed. Mater. Res. 25:1259-1274 (Oct. 1991).Applicant
Chung et al., Inner core segment design for drug delivery control of thermo-responsive polymeric micelles, Journal of Controlled Release 65:93-103 (2000).Applicant
Dev et al., Kinetics of Drug Delivery to the Arterial Wall Via Polyurethane-Coated Removable Nitinol Stent: Comparative Study of Two Drugs, Catheterization and Cardiovascular Diagnosis 34:272-278 (1995).Applicant
Dichek et al., Seeding of Intravascular Stents with Genetically Engineered Endothelial Cells, Circ. 80(5):1347-1353 (Nov. 1989).Applicant
Eigler et al., Local Arterial Wall Drug Delivery from a Polymer Coated Removable Metallic Stent: Kinetics, Distribution, and Bioactivity of Forskolin, JACC, 4A (701-1), Abstract (Feb. 1994).Applicant
Helmus, Overview of Biomedical Materials, MRS Bulletin, pp. 33-38 (Sep. 1991).Applicant
Herdeg et al., Antiproliferative Stent Coatings: Taxol and Related Compounds, Semin. Intervent. Cardiol. 3:197-199 (1998).Applicant
Huang et al., Biodegradable Polymers Derived from Aminoacids, Macromol. Symp. 144, 7-32 (1999).Applicant
Inoue et al., An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs, Journal of Controlled Release 51:221-229 (1998).Applicant
Kataoka et al., Block copolymer micelles as vehicles for drug delivery, Journal of Controlled Release 24:119-132 (1993).Applicant
Katsarava et al., Amino Acid-Based Bioanalogous Polymers. Synthesis and Study of Regular Poly(ester amide)s Based on Bis(α-amino acid)α,ω-Alkylene Diesters, and Aliphatic Dicarbolic Acids, Journal of Polymer Science, Part A: Polymer Chemistry, 37(4), 391-407 (1999).Applicant
Levy et al., Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants, Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).Applicant
Liu et al., Drug release characteristics of unimolecular polymeric micelles, Journal of Controlled Release 68:167-174 (2000).Applicant
Marconi et al., Covalent bonding of heparin to a vinyl copolymer for biomedical applications, Biomaterials 18(12):885-890 (1997).Applicant
Matsumaru et al., Embolic Materials for Endovascular Treatment of Cerebral Lesions, J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).Applicant
Miyazaki et al., Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing. Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice, Chem. Pharm. Bull. 33(6) 2490-2498 (1985).Applicant
Miyazawa et al., Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat, J. Cardiovasc. Pharmacol., pp. 157-162 (1997).Applicant
Nordrehaug et al., A novel biocompatible coating applied to coronary stents, EPO Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).Applicant
Ohsawa et al., Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty, American Heart Journal 136(6):1081-1087 (Dec. 1998).Applicant
Ozaki et al., New Stent Technologies, Progress in Cardiovascular Diseases, vol. XXXIX(2):129-140 (Sep./Oct. 1996).Applicant
Pechar et al., Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin, Bioconjucate Chemistry 11(2):131-139 (Mar./Apr. 2000).Applicant
Peng et al., Role of polymers in improving the results of stenting in coronary arteries, Biomaterials 17:685-694 (1996).Applicant
Saotome, et al.,.Novel Enzymatically Degradable Polymers Comprising α-Amino Acid, 1,2-Ethanediol, and Adipic Acid, Chemistry Letters, pp. 21-24, (1991).Applicant
Shigeno, Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor, Chemical Abstract 125:212307 (1996).Applicant
van Beusekom et al., Coronary stent coatings, Coronary Artery Disease 5(7):590-596 (Jul. 1994).Applicant
Wilensky et al., Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries, Trends Cardiovasc Med 3(5):163-170 (1993).Applicant
Yokoyama et al., Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor, Journal of Controlled Release 50:79-92 (1998).Applicant

Description

BACKGROUND OF THE INVENTION

[0001] 1. Field of the Invention

[0003] 2. Description of the Background

[0006] Therefore, there is a need for the preservation of BHT and/or BHA in a stent manufacturing process. There is another need for the incorporation of BHT and/or BHA into the drug product.

[0007] The embodiments described below address the above described problems and needs.

SUMMARY OF THE INVENTION

BRIEF DESCRIPTION OF DRAWINGS

[0010] FIG. 1 shows one embodiment of the present invention where an antioxidant is placed in a porous or permeable container in a product package containing a medical device;

[0013] FIG. 4 shows butylated hydroxytoluene (BHT) powder sublimation at different temperature;

[0014] FIG. 5 shows BHT retained in a coating at different temperatures.

DETAILED DESCRIPTION

Permeation of a Volatile Antioxidant into a Coating

[0018]

	TABLE 1

	Material	Time to reach permeation rate of 1 μg/cm²/min)


	ETO	120
	Cresol	206
	Toluene	>480

[0029] In another preferred embodiment, the biobeneficial material can be a polyether such as polyethylene glycol (PEG) or polyalkylene oxide.

Examples of Medical Device

Method of Use

Example

Study of BHT Loss in the Stent Manufacture Process

Experiment Results and Discussion

Table 2 listed sampling schemes for the tested sample stents.

[0035]

TABLE 2

Sampling scheme
		# of stent	# of stent
Stent		for BHT	for drug
Label	Sampling steps	test	content

1	After stent secured on the balloon	5	4
	and packaged in Tyvek pouch
2	After ETO sterilization	5	4

[0036] Table 3 is a summary of BHT and total content of the drug (TC) test results at the various stages of stent manufacture process.

[0037]

TABLE 3

Summary of BHT and TC test results
			BHT found,	% BHT	% BHT
Groups	Conditions	TC, %	ng/ug drug	retained	loss

	Raw drug		1.78	100	0
	Drug coat solution		1.80	101.1	0
1	before ETO	98.5	0.97	54.6	45.4
2	Post ETO	94.8	0.11	5.9	94.1

[0039]

\begin{matrix} Ln \frac{BHT}{{BHT}_{0}} = - kt & (1) \end{matrix}

[0040] Based on the curve fitting in FIG. 5, k_40C=0.048 and k_50C=0.1331. Using Arrhenius equation (Equation 2),

[0041]

\begin{matrix} Ln \frac{k_{2}}{k_{1}} = \frac{E_{a}}{R} [\frac{T_{2} - T_{1}}{T_{1} T_{2}}] & (2) \end{matrix}